ClinicalTrials.gg

Program

Acne mRNA vaccine

Its studies are mostly in Acne Vulgaris, led by Sanofi.

Furthest: phase 2, since Mar 12, 20242 company-led studies, 2 open or runningNext primary completion: Nov 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi22 open or runningphase 2since Mar 12, 2024Mar 12, 2024Nov 30, 2028phase 2 · NCT06316297

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2024First study: phase 2 study in Acne VulgarisFirst studyNCT06316297 · 800 planned · United States, Australia, Canada and more
  2. Jun 2, 2025Phase 2 study in Acne VulgarisNCT07013747 · 228 planned · United States

Ahead

  1. Nov 30, 2028Primary completion: phase 2 study in Acne VulgarisNCT06316297
  2. Jun 19, 2029Primary completion: phase 2 study in Acne VulgarisNCT07013747

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Acne mRNA vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07013747Acne Vulgaris · United States2RecruitingJun 19, 2029228
NCT06316297Acne Vulgaris · United States, Australia, Canada and more2RecruitingNov 30, 2028800

How it is read

Names in the registry

  • “Acne mRNA vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.